JP2019524702A - テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト - Google Patents

テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト Download PDF

Info

Publication number
JP2019524702A
JP2019524702A JP2019500301A JP2019500301A JP2019524702A JP 2019524702 A JP2019524702 A JP 2019524702A JP 2019500301 A JP2019500301 A JP 2019500301A JP 2019500301 A JP2019500301 A JP 2019500301A JP 2019524702 A JP2019524702 A JP 2019524702A
Authority
JP
Japan
Prior art keywords
hydrocarbyl
patient
compound according
tetrahydro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019500301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524702A5 (https=
Inventor
エス． コラー，バリー
エス． コラー，バリー
フィリゾラ，マルタ
アンドリュー フォーリー，マイケル
アンドリュー フォーリー，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2019524702A publication Critical patent/JP2019524702A/ja
Publication of JP2019524702A5 publication Critical patent/JP2019524702A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019500301A 2016-07-05 2017-07-05 テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト Pending JP2019524702A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662358330P 2016-07-05 2016-07-05
US62/358,330 2016-07-05
US201662374234P 2016-08-12 2016-08-12
US62/374,234 2016-08-12
PCT/US2017/040657 WO2018009501A1 (en) 2016-07-05 2017-07-05 Tetrahydronaphthyridinepentanamide integrin antagonists

Publications (2)

Publication Number Publication Date
JP2019524702A true JP2019524702A (ja) 2019-09-05
JP2019524702A5 JP2019524702A5 (https=) 2020-08-13

Family

ID=60912284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500301A Pending JP2019524702A (ja) 2016-07-05 2017-07-05 テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト

Country Status (9)

Country Link
US (1) US11192889B2 (https=)
EP (1) EP3481814B1 (https=)
JP (1) JP2019524702A (https=)
KR (1) KR20190026001A (https=)
CN (1) CN109476632A (https=)
AU (1) AU2017292754B2 (https=)
CA (1) CA3029829A1 (https=)
MX (1) MX2019000043A (https=)
WO (1) WO2018009501A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021509890A (ja) * 2018-03-07 2021-04-08 プライアント・セラピューティクス・インコーポレイテッドＰｌｉａｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アミノ酸化合物および使用方法
US11419869B2 (en) 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
AU2019318538B2 (en) 2018-08-08 2025-02-06 The General Hospital Corporation Polypeptide integrin antagonists
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
SI3844162T1 (sl) 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
TW202329973A (zh) * 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途
WO2024125634A1 (zh) * 2022-12-16 2024-06-20 西藏海思科制药有限公司 一种四氢萘啶类化合物及其在医药上的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139398A1 (en) * 2001-04-09 2003-07-24 Hoekstra William J. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
JP2003277340A (ja) * 2002-03-22 2003-10-02 Toray Ind Inc 接着分子阻害剤及び新規アミノ酸誘導体
US20040038963A1 (en) * 2000-07-26 2004-02-26 Jiabing Wang Alpha v integrin receptor antagonists
US6784190B2 (en) * 1997-12-17 2004-08-31 Merck & Co., Inc. Integrin receptor antagonists
US6838453B2 (en) * 2000-05-09 2005-01-04 Aventis Pharma S.A. Antagonist derivatives of the vitronectin receptor
WO2011011775A1 (en) * 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
US20160130270A1 (en) * 2013-02-07 2016-05-12 Scifluor Life Sciences, Inc. Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010033248A (ko) * 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
CN1589145A (zh) * 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
PT2953948T (pt) * 2013-02-07 2017-12-12 Scifluor Life Sciences Inc Antagonistas de integrina fluorada

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6784190B2 (en) * 1997-12-17 2004-08-31 Merck & Co., Inc. Integrin receptor antagonists
US6838453B2 (en) * 2000-05-09 2005-01-04 Aventis Pharma S.A. Antagonist derivatives of the vitronectin receptor
US20040038963A1 (en) * 2000-07-26 2004-02-26 Jiabing Wang Alpha v integrin receptor antagonists
US20030139398A1 (en) * 2001-04-09 2003-07-24 Hoekstra William J. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
JP2003277340A (ja) * 2002-03-22 2003-10-02 Toray Ind Inc 接着分子阻害剤及び新規アミノ酸誘導体
WO2011011775A1 (en) * 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
US20160130270A1 (en) * 2013-02-07 2016-05-12 Scifluor Life Sciences, Inc. Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRASHEAR, KM ET AL.: "Non-Peptide αvβ3 Antagonists. Oart 5: Identification of Potent RGD Mimetics Incorporating 2-Aryl", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, JPN6021018673, 2002, pages 3483 - 3486, ISSN: 0004508638 *
WHITMAN, DB ET AL.: "Nonpeptide αvβ3 antagonists. Part 9: Inproved pharmacokinetic profile through the use of an alipha", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, JPN6021018672, 2004, pages 4411 - 4415, ISSN: 0004508637 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021509890A (ja) * 2018-03-07 2021-04-08 プライアント・セラピューティクス・インコーポレイテッドＰｌｉａｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アミノ酸化合物および使用方法
US11560376B2 (en) 2018-03-07 2023-01-24 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11419869B2 (en) 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
US12390463B2 (en) 2019-04-08 2025-08-19 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds

Also Published As

Publication number Publication date
KR20190026001A (ko) 2019-03-12
EP3481814A4 (en) 2019-12-04
EP3481814A1 (en) 2019-05-15
WO2018009501A1 (en) 2018-01-11
EP3481814B1 (en) 2022-04-27
CA3029829A1 (en) 2018-01-11
AU2017292754A1 (en) 2019-01-24
AU2017292754B2 (en) 2021-06-17
US11192889B2 (en) 2021-12-07
CN109476632A (zh) 2019-03-15
MX2019000043A (es) 2019-07-04
US20200181138A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
US11192889B2 (en) Tetrahydronaphthyridinepentanamide integrin antagonists
KR102866916B1 (ko) Lpa 수용체 길항제 및 이의 용도
KR102775995B1 (ko) Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
US7410984B2 (en) Compounds
US7550481B2 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
EP2927231B1 (en) Imidazopyridine compounds
JP4491072B2 (ja) ビトロネクチンレセプター拮抗物質
US8030489B2 (en) Ornithine derivative
JP6353072B2 (ja) カンナビノイド受容体アゴニストとしての５，６−二置換ピリジン−２−カルボキサミド
JP2005522438A (ja) ピリミジン化合物
TWI598348B (zh) 雜環化合物及其用途
CA3218569A1 (en) Lpa receptor antagonists and uses thereof
WO2018222917A1 (en) Ire1 small molecule inhibitors
KR20010024141A (ko) 비트로넥틴 수용체 길항 물질
IL296632A (en) phd inhibitory compounds, compositions and use
TW202235078A (zh) 自分泌運動因子（ａｕｔｏｔａｘｉｎ）之新穎的抑制劑
TWI917364B (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法
TWI624466B (zh) 苯并噻吩化合物
CN113015736B (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
MXPA00002700A (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201